The data encompasses the first three cohorts of a dose escalation trial to demonstrate the safety of MCY-M11 and the feasibility of one-day manufacturing
() has said it will present clinical data from an ongoing phase one trial of its MCY-M11 treatment for ovarian cancer and peritoneal mesothelioma at the American Society of Clinical Oncology's upcoming annual meeting.
The cell-based therapy specialist said the data, which encompasses the first three cohorts of a dose-escalation trial to demonstrate the safety of MCY-M11 and the feasibility of one-day manufacturing, will be available as a poster presentation in the Developmental Therapeutics: Immunotherapy session from 8am Eastern Time (1pm BST) on May 29.
WATCH: MaxCyte deal with Caribou 'demonstrates expertise and value' of its Flow Electroporation technology
The presentation will be entitled: "Feasibility and preliminary safety and efficacy of first-in-human intraperitoneal delivery of MCY-M11, anti-human-mesothelin CAR mRNA transfected into peripheral blood mononuclear cells, for ovarian cancer and malignant peritoneal mesothelioma."
The third cohort began dosing in the MCY-M11 trial in October 2019, while a fourth cohort commenced dosing in March this year.
Preliminary clinical results for the trial are expected to be announced in the second half of 2020.
MaxCyte shares rose 2.9% to 180p in early deals on Thursday.